Lumexa Imaging's Dr. Jennifer L. Kemp Elected to RSNA Board, Advancing National Leadership in Quality and Patient-Centered Care
Rhea-AI Summary
Lumexa Imaging (NASDAQ: LMRI) announced that Jennifer L. Kemp, MD, Chair of its Center for Quality, was elected to the Radiological Society of North America (RSNA) Board of Directors and will serve as board liaison for government relations.
The company highlights Dr. Kemp's focus on patient-centered care and notes Lumexa's use of Scanslated AI-driven software, which has delivered over 2 million reports to patients and yielded a 99% positive survey response on likelihood to choose Lumexa centers.
Positive
- None.
Negative
- None.
News Market Reaction – LMRI
In the Jan 28 session, LMRI declined 2.75%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-01-08 | Expansion update | Positive | +2.5% | Record nine de novo outpatient centers opened in 2025 across multiple states. |
| 2026-01-05 | Conference participation | Positive | +3.3% | Management presenting at major healthcare investor conference with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news — expansion and investor outreach — has been followed by positive price reactions, suggesting the stock has responded constructively to growth and visibility updates.
In early January 2026, Lumexa highlighted record de novo expansion, opening nine new outpatient imaging centers in 2025 and reaching more than 185 centers across 13 states, which coincided with a 2.49% gain. Shortly after, news of participation in the 44th Annual J.P. Morgan Healthcare Conference preceded a 3.33% move higher. Against this backdrop, today’s governance and clinical-leadership recognition fits a narrative of growth, visibility, and quality positioning.
Key Terms
ai-driven software technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Chair of Lumexa Imaging's Center for Quality will serve as the Radiological Society of
"Dr. Kemp's election to the RSNA Board reflects the depth of clinical leadership within our organization and the important role our physicians play in shaping the future of radiology," said Caitlin Zulla, CEO of Lumexa Imaging. "Her commitment to patient-centered care and quality advancement is especially critical as our industry navigates growth, AI innovation, and evolving policy environments."
In addition to her role at Lumexa Imaging, Dr. Kemp serves as Chief of Patient Experience at Scanslated, where she leads initiatives focused on improving patient understanding of radiology results. Lumexa Imaging utilizes Scanslated's AI-driven software as a key part of its technology platform, supporting the company's differentiated approach to patient engagement by translating complex radiology reports into clear, patient-friendly language.
To date, Lumexa Imaging patients have accessed more than 2 million reports through the Scanslated platform. Among recently surveyed patients who used the Scanslated platform,
"I'm honored to serve on the RSNA Board and to take on the role of liaison for government relations at a pivotal time of growth in radiology," said Dr. Kemp. "Through my role with RSNA, I intend to help guide radiology in a direction that ensures patients continue to receive the highest quality of care while strengthening the voice of radiologists in shaping our future. This work closely aligns with Lumexa Imaging's commitment to advancing clinical excellence and improving the patient experience through innovation and thoughtful leadership."
About Lumexa Imaging
Lumexa Imaging (NASDAQ: LMRI) is a nationwide provider of outpatient medical imaging. With over 5,000 team members and more than 185 outpatient imaging centers across 13 states, our team conducted approximately 4 million outpatient scans in 2024. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this press release, including statements regarding our implementation of technology, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as "may," "would," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, results of operations, liquidity and stock price. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Forward-looking statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.
Media Contact
Melissa Weston
corpcomms@lumexaimaging.com
IR Contact
IR@lumexaimaging.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lumexa-imagings-dr-jennifer-l-kemp-elected-to-rsna-board-advancing-national-leadership-in-quality-and-patient-centered-care-302672000.html
SOURCE Lumexa Imaging